Show Summary Details
Page of

Systemic therapy for advanced colorectal cancer 

Systemic therapy for advanced colorectal cancer
Systemic therapy for advanced colorectal cancer

Fiona Collinson

, Peter Hall

, Mike Braun

, and Daniel Swinson

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 05 August 2021

Over the past two decades the median overall survival for patients with advanced colorectal cancer has increased from 6 months without treatment to 2 years with modern systemic therapies

The standard chemotherapy armamentarium includes fluoropyrimidines, oxaliplatin and irinotecan delivered in two lines of treatment. Irinotecan and fluoropyrimidines have single agent activity but oxaliplatin is only effective in combination with a second drug

Infusional 5-fluorouracil can be substituted with capecitabine without loss of efficacy. Caution should be exercised in the elderly and in the presence of even modest renal impairment

Controversy persists on the worth of newer biological drugs targeting EGFR and VEGF

Current research aims to identify new agents and develop a tailored approach dependent on predictive clinicopathological and biological markers.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.